(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million. (Reporting by Bipasha
Sanofi Agrees to $470 Million Acquisition of Vigil Neuroscience
(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
(Reporting by Bipasha Dey in Bengaluru; Editing by Mohammed Safi Shamsi)


